logo
XTRA:HPHA logo

Heidelberg Pharma Community

XTRA:HPHA Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

HPHA logo
Heidelberg Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts

ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers

Key Takeaways Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings. Secure financial strategy through non-dilutive financing strengthens its position, supporting R&D and reducing risk.
View narrative
€10.70
FV
68.4% undervalued intrinsic discount
48.24%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
about 1 month ago author updated this narrative